DaShenLin Pharmaceutical Group Co (SHSE:603233) ROC %: 13.93% (As of Mar. 2026)


SHSE:603233 DaShenLin Pharmaceutical Group Co Ltd SHSE:603233
95 GF Score
Price ¥15.03
GF Value ¥18.69
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is DaShenLin Pharmaceutical Group Co ROC %?

DaShenLin Pharmaceutical Group Co SHSE:603233 -2.91% 95 ROC % is 13.93% as of Mar. 2026. GuruFocus rates SHSE:603233 with a GF Score™ of 95/100 and a GF Value™ of ¥18.69 (Modestly Undervalued). The stock has 4 warning signs investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. DaShenLin Pharmaceutical Group Co's annualized return on capital (ROC %) for the quarter that ended in Mar. 2026 was 13.93%.

As of today (2026-06-30), DaShenLin Pharmaceutical Group Co's WACC % is 8.59%. DaShenLin Pharmaceutical Group Co's ROC % is 9.84% (calculated using TTM income statement data). DaShenLin Pharmaceutical Group Co generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


DaShenLin Pharmaceutical Group Co  (SHSE:603233) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, DaShenLin Pharmaceutical Group Co's WACC % is 8.59%. DaShenLin Pharmaceutical Group Co's ROC % is 9.84% (calculated using TTM income statement data). DaShenLin Pharmaceutical Group Co generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


DaShenLin Pharmaceutical Group Co ROC % Related Terms


DaShenLin Pharmaceutical Group Co ROC % Historical Data

* Premium members only.

The historical data trend for DaShenLin Pharmaceutical Group Co's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DaShenLin Pharmaceutical Group Co ROC % Chart

DaShenLin Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.70 11.03 10.41 7.20 9.14

DaShenLin Pharmaceutical Group Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.64 9.40 8.98 6.79 13.93
SHSE:603233
95GF Score
DaShenLin Pharmaceutical Group Co Ltd SHSE:603233
ROC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DaShenLin Pharmaceutical Group Co ROC % Calculation

DaShenLin Pharmaceutical Group Co's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=2095.192 * ( 1 - 26.52% )/( (17280.316 + 16416.158)/ 2 )
=1539.5470816/16848.237
=9.14 %

where

Invested Capital(A: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=26439.81 - 10280.122 - ( 6232.283 - max(0, 13706.845 - 12586.217+6232.283))
=17280.316

Invested Capital(A: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=26486.999 - 11757.803 - ( 6948.326 - max(0, 15067.465 - 13380.503+6948.326))
=16416.158

DaShenLin Pharmaceutical Group Co's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=2937.032 * ( 1 - 23.12% )/( (16416.158 + 16006.547)/ 2 )
=2257.9902016/16211.3525
=13.93 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=26486.999 - 11757.803 - ( 6948.326 - max(0, 15067.465 - 13380.503+6948.326))
=16416.158

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=26830.178 - 11913.436 - ( 7110.829 - max(0, 14967.965 - 13878.16+7110.829))
=16006.547

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of 13.93% mean?
DaShenLin Pharmaceutical Group Co (SHSE:603233) has a ROC % of 13.93% as of Mar. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on DaShenLin Pharmaceutical Group Co and its competitors.
Is DaShenLin Pharmaceutical Group Co's ROC % too high?
DaShenLin Pharmaceutical Group Co's current ROC % is 13.93%. The Healthcare Providers & Services industry median ROC % is 3.08. DaShenLin Pharmaceutical Group Co's value of 13.93% is 353% above this industry median. Overall, DaShenLin Pharmaceutical Group Co has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DaShenLin Pharmaceutical Group Co's ROC % compare to competitors?
DaShenLin Pharmaceutical Group Co's ROC % of 13.93% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROC % is 3.08. DaShenLin Pharmaceutical Group Co's value of 13.93% is 353% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Healthcare Providers & Services company?
The median ROC % among Healthcare Providers & Services companies is 3.08, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a ROC % significantly above this median, while those in the bottom quartile fall well below. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DaShenLin Pharmaceutical Group Co's current ROC % of 13.93% is 353% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on DaShenLin Pharmaceutical Group Co and its competitors. For the Healthcare Providers & Services industry, the median ROC % is 3.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DaShenLin Pharmaceutical Group Co's current ROC % is 13.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DaShenLin Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, DaShenLin Pharmaceutical Group Co (SHSE:603233) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥18.69, compared to a current price of ¥15.03 — trading 19.6% below its estimated fair value. The current ROC % is 13.93% and 353% above the Healthcare Providers & Services industry median of 3.08. DaShenLin Pharmaceutical Group Co's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For DaShenLin Pharmaceutical Group Co (SHSE:603233), the current ROC % is 13.93% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DaShenLin Pharmaceutical Group Co (SHSE:603233) Overvalued in 2026?

Based on GuruFocus' analysis, DaShenLin Pharmaceutical Group Co stock appears to be undervalued. The current stock price of ¥15.03 is trading 19.6% below its estimated GF Value™ of ¥18.69. GuruFocus considers DaShenLin Pharmaceutical Group Co to be Modestly Undervalued.

Key valuation signals for SHSE:603233:

  • ROC %: 13.93%
  • GF Value™: ¥18.69 vs. price of ¥15.03 (19.6% below fair value)
  • GF Score™: 95/100 with 4 warning signs
  • Industry Position: 353% above the Healthcare Providers & Services median

No single metric tells the full story. See the SHSE:603233 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


DaShenLin Pharmaceutical Group Co Business Description

Address No. 410-1, Longxi Avenue, Liwan District, Guangdong Province, Guangzhou, CHN, 510000
DaShenLin Pharmaceutical Group Co Ltd is engaged in the pharmaceutical manufacturing, retail, and wholesale business. The company is based on the development of the pharmacy chain. It primarily offers Chinese herbal medicine such as antibiotics and biochemical drugs. The business activities are geographically carried out through China.
95GF Score

Get the complete analysis for SHSE:603233

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥15.03
Price
¥18.69
GF Value